← ZEVRA THERAPEUTICS, INC. (ZVRA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ZEVRA THERAPEUTICS, INC. (ZVRA)
Pharmaceutical Preparations · market cap $663M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Zevra Therapeutics (ZVRA) is a small-cap pharmaceutical company (~$755M market cap, 59 employees) with two clinical-stage assets: KP415, an oral capsule in Phase 3 for ADHD, and Serdexmethylphenidate in Phase 2 for Idiopathic Hypersomnia. The company posted $106M in revenue in 2025 — a sharp jump from $24M in 2024 — while swinging to net income of $83M, suggesting a recently approved or commercially ramping product, though the specific commercialized asset is not identified in the provided facts.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KP415 oral capsule | Phase 3 | ADHD |
| Serdexmethylphenidate | Phase 2 | Idiopathic Hypersomnia |
Price & technical context
3-month
-27.2%
6-month
+8.2%
12-month
+8.0%
52-wk range
$8.10–$14.75
vs 50-day MA
-10.5%
vs 200-day MA
-3.5%
Realized vol
67.5%
Max drawdown
-43.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ZVRA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.